{"doi":"10.1111/ejh.13477","title":"A population‐based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival","abstract":"OBJECTIVE: Infections in chronic lymphocytic leukemia (CLL) have been thoroughly investigated in the setting of clinical trials and single-center studies. However, large cohort studies on real-world data and studies on temporal trends are lacking. We performed a nationwide study on serious bacterial infections in CLL. METHODS: Using high-quality Swedish government-based registries, 13 009 CLL patients diagnosed in 1982-2013 and their 49 380 matched controls were included. RESULTS: Overall, CLL patients had an increased risk of serious inpatient bacterial infections with a hazard ratio (HR) 5.32 and 95% confidence interval (95% CI) 5.11-5.53, and the highest risk was observed for septicemia (HR 6.91, 95% CI 6.46-7.39) and lung infections (5.91, 5.64-6.18). The risk of serious inpatient bacterial infections decreased overtime with HR 0.87 (0.81-0.94) and HR 0.76 (0.70-0.82) in 1993-2002 and 2003-2013, respectively, compared to 1982-1992. CLL patients had an increased risk of death following a serious inpatient bacterial infection compared to matched CLL patients, and the risk was highest in the first 12 months after the infection (HR 5.48, 95% CI 5.11-5.90). CONCLUSION: We have, in this nationwide study, characterized the risk of serious bacterial infections in CLL patients and, importantly, depicted that the risk has decreased overtime.","journal":"European Journal Of Haematology","year":2020,"id":111800,"datarank":0.2792825918907439,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.03786690502562879,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.03786690502562879,"corpus_percentile":43.04943142260385,"corpus_rank":7363,"citation_count":4,"citer_count":4,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.6991,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":531029,"name":"Gauti K. Gíslason","orcid":null,"position":1,"is_corresponding":false},{"id":38471,"name":"Thor Aspelund","orcid":"0000-0002-7998-5433","position":2,"is_corresponding":false},{"id":452697,"name":"Ingemar Turesson","orcid":"0000-0002-4115-8010","position":3,"is_corresponding":false},{"id":453794,"name":"Magnus Björkholm","orcid":null,"position":4,"is_corresponding":false},{"id":254707,"name":"Ola Landgren","orcid":"0000-0001-6485-4839","position":5,"is_corresponding":false},{"id":452698,"name":"Sigurður Y. Kristinsson","orcid":"0000-0002-4964-7476","position":6,"is_corresponding":false},{"id":452693,"name":"Vilhjálmur Steingrímsson","orcid":"0000-0002-9385-2960","position":0,"is_corresponding":true}],"reference_count":31,"raw_metadata":null,"created_at":"2026-07-18T23:13:09.353152Z","pmid":"32575150","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}